Back to top

Image: Bigstock

Albemarle (ALB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Read MoreHide Full Article

Albemarle (ALB - Free Report) reported $1.33 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 7%. EPS of $0.11 for the same period compares to $0.04 a year ago.

The reported revenue represents a surprise of +6.98% over the Zacks Consensus Estimate of $1.24 billion. With the consensus EPS estimate being -$0.83, the EPS surprise was +113.25%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Albemarle performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Net Sales- Energy Storage: $717.66 million compared to the $589.35 million average estimate based on five analysts. The reported number represents a change of -13.6% year over year.
  • Net Sales- Ketjen: $260.78 million versus $259.99 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1.8% change.
  • Net Sales- Specialties: $351.56 million versus $344.69 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
  • Adjusted EBITDA- Energy Storage: $219.73 million compared to the $118.06 million average estimate based on five analysts.
  • Adjusted EBITDA- Corporate: $15.21 million versus $-17.52 million estimated by five analysts on average.
  • Adjusted EBITDA- Ketjen: $28.57 million versus $31.27 million estimated by five analysts on average.
  • Adjusted EBITDA- Specialties: $72.98 million versus the five-analyst average estimate of $54.9 million.

View all Key Company Metrics for Albemarle here>>>

Shares of Albemarle have returned +13.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Albemarle Corporation (ALB) - free report >>

Published in